Hongbo Lu
Hongbo Lu's purchase track record
How the stock did after each of Hongbo Lu's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/31/2026 | ZBIO | $1.57M | +29.8% | +36.9% | +17.5% |
| 2/11/2026 | ZBIO | $585K | -14.3% | +34.5% | +11.6% |
| 10/7/2025 | ZBIO | $5.00M | -27.1% | +7.8% | -1.5% |
| 9/13/2024 | ZBIO | $2.00M | -50.8% | -54.5% | +0.2% |
| 3/18/2024 | ARWR | $83K | -10.8% | -27.3% | +9.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ZBIO releases Phase 3 Obexelimab data, plans MS trial presentations. The company released new Phase 3 results for its Obexelimab program in IgG4‑related disease, which were presented at a recent international symposium. The data release coincided with a 5.1% share decline. Zenas also announced upcoming virtual presentations of Orelabrutinib data for multiple sclerosis at MSToronto2026 and a broader R&D webcast. Analyst HC Wainwright kept its $44 price target, reinforcing its view on the stock.
Transaction History
| ARWR | ▼ Sell | Open Market | 2,970 | $228K | 5/12/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 75,000 | $1.5M | 3/31/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 3,768 | $70K | 3/31/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 25,985 | $585K | 2/11/2026 | View on chart |
| ARWR | ▲ Buy | Grant | 7,819 | $0 | 12/16/2025 | View on chart |
| ZBIO | ▲ Buy | Open Market | 263,160 | $5.0M | 10/7/2025 | View on chart |
| ARWR | ▲ Buy | Grant | 16,733 | $385K | 12/18/2024 | View on chart |
| ZBIO | ▲ Buy | Open Market | 58,823 | $1000K | 9/13/2024 | View on chart |
| ZBIO | ▲ Buy | Open Market | 58,823 | $1000K | 9/13/2024 | View on chart |
| ARWR | ▲ Buy | Open Market | 1,000 | $28K | 3/20/2024 | View on chart |
| ARWR | ▲ Buy | Open Market | 1,000 | $28K | 3/19/2024 | View on chart |
| ARWR | ▲ Buy | Open Market | 1,000 | $27K | 3/18/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value
Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value. Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.